WebMD Medical News
Louise Chang, MD
July 19, 2007 -- Patients with the most common type of leukemia achieved
better responses to treatment with two cancer-fighting drugs than one in a
large international study.
Chronic lymphocytic leukemia (CLL) patients also had much better survival
rates without disease progression when treated with a combination of the
chemotherapeutic drugs fludarabine and cyclophosphamide than patients treated
with fludarabine alone or another single-agent chemotherapy, chlorambucil.
The study is the third in two years to find greatly improved clinical
outcomes among CLL patients treated with the combination regimen.
Together, the studies show that fludarabine plus cyclophosphamide should be
considered a standard, first-line treatment for CLL, Daniel Catovsky, FRCP, of
the Institute of Cancer Research in Sutton, England, tells WebMD.
The study appears in the July 21 issue of The Lancet.
"We think the combination should be used both in clinical practice and
in clinical trials evaluating new approaches to treatment," he says.
More than 15,000 new cases of CLL will be diagnosed this year in the U.S.,
with most cases occurring in people over 50. In addition to advanced age, it is
more commonly seen in men.
Because CLL progresses slowly -- sometimes over decades -- and people with
early-stage disease have no symptoms, patients are generally not treated until
they are in their 70s or older.
In the U.S., patients are often treated with fludarabine (brand name
Fludara) or chlorambucil (brand name Leukeran).
In the latest study of CLL drugs, Catovsky and colleagues compared outcomes
among patients treated with fludarabine plus the chemotherapy drug
cyclophosphamide (brand name Cytoxan), fludarabine alone, or chlorambucil
A total of 777 study participants with previously untreated CLL were
followed for up to five years. The average age of the patients when they
entered treatment was 65.
While no significant difference in overall survival rates was seen among the
three treatment groups, three times as many patients who got the combination
treatment experienced no progression of their disease at five years (36% vs.
10% for the two single drugs).
Complete responses to treatment were seen in 38% of patients treated with
the two drugs, compared with 15% of patients treated with fludarabine alone and
7% of those treated with chlorambucil alone.
Treatment with fludarabine plus cyclophosphamide was associated with a
higher incidence of potentially dangerous declines in infection-fighting white
blood cells and more days spent in the hospital during treatment.
Overall, the combination treatment was well tolerated, Catovsky says, even
among the oldest patients in the study.
The message that older patients with CLL can tolerate the most aggressive
treatments is one of the most important to come out of this and other recent
studies, says Mayo Clinic College of Medicine assistant professor of medicine
Tait D. Shanafelt, MD.
"Patients over the age of 70 who were physically fit did very well with
this regimen," he tells WebMD. "Age alone should not be considered a
reason to exclude people from aggressive therapy. That is an important
Finding appropriate treatments for CLL patients who are not good candidates
for the most aggressive therapies because of other health conditions or
age-related frailty should also be high on the list, he adds.
"We don't really have a good handle on what the most effective and
tolerable treatments are for these patients," he says.
SOURCES: Catovsky, D. The Lancet, July 21, 2007; vol 370: pp 230-239.
Daniel Catovsky, FRCP, Institute of Cancer Research, Sutton, England. Tait D.
Shanafelt, MD, assistant professor of medicine, Mayo Clinic College of
Medicine, Rochester, Minn. American Cancer Society.
Here are the most recent story comments.View All